Zoetis (ZTS) Stock Forecast & Price Target

Zoetis's strong market position is underscored by its substantial growth in pet owner engagement, with enrollment in the Zoetis Petcare Rewards program surging to 2.5 million from 708,000 in 2018, alongside a significant investment of over $120 million in this initiative and direct-to-consumer marketing in 2023. The company's product lines are also showing impressive performance, as evidenced by Simparica generating $356 million in revenue in Q3, reflecting a year-over-year growth of 7%, while its key dermatological products collectively achieved global revenue of $469 million, up by 3% year-over-year. These factors highlight Zoetis's ability to effectively capitalize on trends within the companion animal market and deliver consistent revenue growth within its diverse product offerings.

Zoetis has lowered its 2025 revenue guidance to a range of $9.400 billion to $9.475 billion, indicating an organic operational growth forecast of only 5.5% to 6.5%, down from a previous estimate that projected growth of 6.5% to 8.0%. The company's performance in the key U.S. companion animal health segment has deteriorated, showing flat growth amid increased competitive pressure and a decline in vet clinic visits, which has resulted in fewer patient starts and subsequently weak sales in its OA pain products. Additionally, the company's stock faced further pressure as investors expressed disappointment over the lack of immediate revenue contributions from its pipeline initiatives, with anticipated benefits shifting to 2027-2030.